Frontiers | EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies | Oncology
Erlotinib - Drugs Details
Figure 1 from Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells. | Semantic Scholar
Mechanism of acquired T790m mutation and action of 3rd generation EGFR... | Download Scientific Diagram
Cancers | Free Full-Text | Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment | HTML
Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy | Clinical Cancer Research
Figure 1 from Current Adjuvant Therapeutic Approaches for Pancreatic Cancer | Semantic Scholar
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
Erlotinib | SpringerLink
Tarceva ( erlotinib )
PLOS ONE: Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pha
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer | Clinical Cancer Research
InOncology - Afatinib NSCLC Treatment | Information | Boehringer Ingelheim
Mechanisms of EGFR inhibitor resistance and therapeutic strategies. | Download Scientific Diagram
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer | Clinical Cancer Research
Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression | Cancer Research
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/ erlotinib and to ALK inhibitor crizotinib - Lung Cancer
Erlotinib Tarceva Dosage & Uses, Side Effects and Treatment Medication by asukaccp - issuu
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer - Lung Cancer
Critical appraisal of the role of gefitinib in the management of local | OTT
Afatinib mechanism of action. Notes: From Hirsh, 45 with permission.... | Download Scientific Diagram
A) Erlotinib bound to the epidermal growth factor receptor (EGFR)... | Download Scientific Diagram
